Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May 23;73(20):460-466.
doi: 10.15585/mmwr.mm7320a3.

Monkeypox Virus Infections After 2 Preexposure Doses of JYNNEOS Vaccine - United States, May 2022-May 2024

Monkeypox Virus Infections After 2 Preexposure Doses of JYNNEOS Vaccine - United States, May 2022-May 2024

Sarah Anne J Guagliardo et al. MMWR Morb Mortal Wkly Rep. .

Abstract

Two doses of JYNNEOS vaccine are effective in preventing many mpox cases and can reduce the severity of symptoms in infected persons. However, infections among fully vaccinated persons can occur. During May 2022-May 2024, a total of 271 mpox cases among fully vaccinated persons were reported to CDC from 27 U.S. jurisdictions. These reported infections are estimated to have occurred in <1% of fully vaccinated persons. Compared with cases among unvaccinated persons, infections among fully vaccinated persons were more likely to occur among non-Hispanic White men aged 30-39 years, were associated with increased numbers of sexual partners, and resulted in less severe disease (p<0.001). Among infections in fully vaccinated persons with complete data, infections after vaccination were reported more commonly after receipt of heterologous (subcutaneous and intradermal) (46%) or homologous subcutaneous (32%) JYNNEOS vaccination than after homologous intradermal (22%) vaccination. Disparate time intervals from vaccination to infection among fully vaccinated persons suggest that immunity is not waning. The median interval between the second vaccine dose and illness onset was longer for cases among persons who had received 2 intradermal doses (median = 363 days; IQR = 221-444 days) compared with cases in persons who had received 2 subcutaneous doses (median = 263 days; IQR = 47-334 days) (p<0.001). The implications of this finding are not known; however, these data should increase confidence in the effectiveness of vaccine doses that were administered intradermally, the preferred method of administration during the peak of the outbreak when vaccine supply was limited. Persons recommended to receive the JYNNEOS vaccine should receive 2 doses, irrespective of the route of administration, and at this time, additional doses are not recommended for the affected population.

PubMed Disclaimer

Conflict of interest statement

All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.

Figures

FIGURE
FIGURE
Proportion of fully vaccinated mpox cases among all mpox cases, by epidemiologic week — United States, May 2022–May 2024 * Probable or confirmed cases in persons who received 2 JYNNEOS doses, with the most recent dose received ≥14 days before illness onset and with vaccination dates occurring since May 2022.

Similar articles

Cited by

References

    1. Minhaj FS, Ogale YP, Whitehill F, et al.; Monkeypox Response Team 2022. Monkeypox outbreak—nine states, May 2022. MMWR Morb Mortal Wkly Rep 2022;71:764–9. 10.15585/mmwr.mm7123e1 - DOI - PMC - PubMed
    1. Dalton AF, Diallo AO, Chard AN, et al.; CDC Multijurisdictional Mpox Case Control Study Group. Estimated effectiveness of JYNNEOS vaccine in preventing mpox: a multijurisdictional case-control study—United States, August 19, 2022–March 31, 2023. MMWR Morb Mortal Wkly Rep 2023;72:553–8. 10.15585/mmwr.mm7220a3 - DOI - PMC - PubMed
    1. Deputy NP, Deckert J, Chard AN, et al. Vaccine effectiveness of JYNNEOS against mpox disease in the United States. N Engl J Med 2023;388:2434–43. 10.1056/NEJMoa2215201 - DOI - PMC - PubMed
    1. Rosenberg ES, Dorabawila V, Hart-Malloy R, et al. Effectiveness of JYNNEOS vaccine against diagnosed mpox infection—New York, 2022. MMWR Morb Mortal Wkly Rep 2023;72:559–63. 10.15585/mmwr.mm7220a4 - DOI - PMC - PubMed
    1. Hazra A, Zucker J, Bell E, et al.; SHARE-NET writing group. Mpox in people with past infection or a complete vaccination course: a global case series. Lancet Infect Dis 2024;24:57–64. 10.1016/S1473-3099(23)00492-9 - DOI - PubMed

Substances